Our Website Uses Cookies 

We and the third parties that provide content, functionality, or business services on our website may use cookies to collect information about your browsing activities in order to provide you with more relevant content and promotional materials, on and off the website, and help us understand your interests and improve the website.

For more information, please contact us or consult our Privacy Notice.

Your binder contains too many pages, the maximum is 40.

We are unable to add this page to your binder, please try again later.

This page has been added to your binder.

Covington Advises Abbott Laboratories in $3.7 Billion Acquisition of Kos Pharmaceuticals, Inc.


NEW YORK, NY, November 6, 2006 — Abbott Laboratories (NYSE: ABT) announced the acquisition of Kos Pharmaceuticals (NASDAQ: KOSP) through a cash tender offer of $78.00 per common share, or $3.7 billion.

Covington & Burling LLP represented Abbott in the transaction. Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics.

The Covington team was led by Catherine Dargan, John Hurvitz and Scott Smith and included corporate associates Andrew Ment, Marianna Horton, Ingrid Loreen, Marcus Weiss and Michael Tzartzouras.

Other members of the team included Stephen Infante (m&a), Peter Safir and Grail Sipes (FDA regulatory), Scott Schrader (patents), Mike Francese and Katherine Gongora (benefits), Robert Gage and Heather Haberl (real estate), Corinne Goldstein (environmental), Rob Heller (tax) and, Maja Baumann, Andria Boateng, Laura Derr, Sarah Hoagland, Maarika Liivak, Christopher Moody, Don Ridings, Chelsea Tanaka-Delgado, Tyra Williams, Jacqueline Wolff, and Jeffrey Wu.

Share this article: